Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopa...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f5227cc382474f8ebf9f507187229834 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer.Case report: A patient with radiation maculopathy and papillopathy was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography, and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visual acuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peripapillary hemorrhage, and macular edema. OCT demonstrated complete resolution of serous retinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocular or systemic side effects were observed.Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy and papillopathy. Antivascular endothelial growth factor therapy may decrease tissue injury associated with radiation vasculopathy.Keywords: bevacizumab, radiation, maculopathy, papillopathy |
|---|